pretickt

When does Regeneron report earnings?

Regeneron Pharmaceuticals, Inc. · end-of-day data as of Nov 13, 2026

Regeneron
REGN · $98.82B
$955.47+0.4%
Nov 13, 2026 · close
$800$900SepOctNov9:3016:003 months +17.9%Nov 13 · close
▲ 7
  • ConsensusBuy · 29
  • P/E vs sector-34.5%
  • Trendbullish
  • MAs4 of 4
  • MA20×50Golden 9d ago
  • MACD5.33
  • Sector▲ +15.9%
Neutral
  • Earnings in76d
  • P/E21.1x
  • RSI68
  • Support-11.4%
  • Off 52w high-3.7%
  • Volume0.9x
  • Bollingerupper half
  • News0.00
  • FCF yield+3.6%
  • 52w range$592–$992
  • ATR+3.3%
  • Off ATH-21.1%
▼ 3
  • PT$893.88 -6.4%
  • P/E vs own+21.4%
  • Insiders-$51.9M

Updates with the 15-min delayed price. Not a forecast or investment advice.

Regeneron REGN reports its next earnings on Thursday, Jan 28, 2027, before the open, an estimated date the company has not confirmed yet. Analysts expect EPS of $25.39 on revenue of $5.85B. Regeneron beat the EPS estimate in 7 of its last 8 reports, and the stock moved ±6.6% on average the session after. The last report, on Oct 30, 2026: EPS of $20.07 against $16.51 expected and revenue of $5.12B against $4.58B; the stock rose 13.3% the next session.

The stock around its reports

⇔⇕$512$655$798$941Nov 24Apr 25Sep 25Feb 26Jul 26Dec 26AEADEADAEDEDAAEDEADAEDAAEDE

Last close $955.47 · +16.8% over 2y · E earnings · D dividend · S split · A analyst rating change

Quarterly results

Q3 FY2026: Revenue +36.3% year over year, free cash flow 29.0% of revenue, operating margin 40.0%.

RevenueFree cash flow
Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$5.12B18.45$1.48B88.8%40.0%38.1%
Q2 FY2026Jun 30, 2026$4.29B12.20$334M86.6%33.1%30.2%
Q1 FY2026Mar 31, 2026$3.61B6.75$848M81.4%17.8%20.2%
Q4 FY2025Dec 31, 2025$3.88B7.86$922M84.9%22.7%21.7%
Q3 FY2025Sep 30, 2025$3.75B13.62$1.42B86.1%27.3%38.9%
Q2 FY2025Jun 30, 2025$3.68B12.81$968M85.6%29.4%37.9%
Q1 FY2025Mar 31, 2025$3.03B7.27$774M84.7%19.5%26.7%
Q4 FY2024Dec 31, 2024$3.79B8.06$996M85.1%26.1%24.2%